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Abstract
Background: Factors mediating the invasion of pancreatic cancer cells through the extracellular
matrix (ECM) are not fully understood.
Methods: In this study, sub-populations of the human pancreatic cancer cell line, MiaPaCa-2 were
established which displayed differences in invasion, adhesion, anoikis, anchorage-independent
growth and integrin expression.
Results: Clone #3 displayed higher invasion with less adhesion, while Clone #8 was less invasive
with increased adhesion to ECM proteins compared to MiaPaCa-2. Clone #8 was more sensitive
to anoikis than Clone #3 and MiaPaCa-2, and displayed low colony-forming efficiency in an
anchorage-independent growth assay. Integrins beta 1, alpha 5 and alpha 6 were over-expressed in
Clone #8. Using small interfering RNA (siRNA), integrin β1 knockdown in Clone #8 cells increased
invasion through matrigel and fibronectin, increased motility, decreased adhesion and anoikis.
Integrin alpha 5 and alpha 6 knockdown also resulted in increased motility, invasion through
matrigel and decreased adhesion.
Conclusion: Our results suggest that altered expression of integrins interacting with different
extracellular matrixes may play a significant role in suppressing the aggressive invasive phenotype.
Analysis of these clonal populations of MiaPaCa-2 provides a model for investigations into the
invasive properties of pancreatic carcinoma.
Background
Pancreatic cancer is a devastating disease; it is the eighth
most common cause of death (from cancer in both sexes
combined) in the World, and is responsible for 227,000
deaths per year [1]. The median survival time after tumour
detection is 3-6 months [2], with an all-stage 5-year sur-
vival rate of < 5% [3]. Surgery offers the best possibility for
survival but at time of diagnosis, only 15% of patients are
eligible for resection [4]. The poor outcome is mainly due
to difficulties in early detection, lack of an effective treat-
ment and limited understanding of the biological charac-
teristics of this disease. Intrinsic resistance to
chemotherapy and radiation [5] coupled with its early sys-
tematic dissemination, local tumour progression and
metastatic propensity are associated with pancreatic can-
cer [6].
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The processes involved in tumour cell invasion and
metastasis are complex. The ability of cancer cells to
degrade and adhere to the basement membrane and
metastasise to distant organs is one of the most critical
aspects of cancer. Adhesion molecules, such as integrins
mediate direct cell-cell recognition and cell-matrix inter-
actions [7] are essential for tumour cell migration [8] and
for basement membrane penetration [9]. In pancreatic
cancer, expression of integrins α6β1 [10-12] and αvβ3
[13] have previously been associated with invasion in cell
lines and tissues. However, contrasting results with
respect to tumour type and integrin expression patterns
makes it difficult to draw general conclusions on the role
of specific integrins. Tumour progression and metastasis
are associated with changes in a multitude of integrin sig-
nalling cascades. Transformed cancer cells are often char-
acterised by the loss/reduction of integrin expression
[14,15]. Extracellular matrix (ECM)-ligand binding to an
integrin initiates signals, which are transmitted via differ-
ent, yet interconnecting, pathways and elicit various cell
functions, such as morphological changes, adhesion,
migration and gene activation, all relevant to the meta-
static cascade. The surrounding microenvironment and
adhesion properties of pancreatic tumours and sub-popu-
lations within the tumour may determine which integrins
increase or reduce metastasis in particular tumours [16].
Advanced tumours often contain a variety of sub-popula-
tions, which have differing metastatic potential [17]. Li et
al. [18] identified a highly tumourigenic sub-population
of pancreatic cancer cells expressing the cell surface mark-
ers CD44, CD24, and epithelial-specific antigen (ESA)
capable of self-renewal and increased tumourigenic
potential. The identification of pancreatic cancer stem
cells has many significant implications for the treatment
of pancreatic cancer.
Therefore, in this study, we isolated clonal isogenic sub-
populations, derived from the original pancreatic cancer
cell line, MiaPaCa-2. Clone #3 and Clone #8 exhibit iden-
tical genetic fingerprints with different malignancy-related
phenotypes. We examine how altered integrin expression
including β1, α5 and α6 affects invasion, motility, adhe-
sion and anoikis using RNAi. Furthermore, the role of
integrins in the aggressive invasive phenotype, which cor-
relates with in vitro malignant transformation in this pan-
creatic cancer cell line model, could help to define an
invasion/metastatic-related model for pancreatic cancer.
Methods
Cell lines
The human pancreatic cell line MiaPaCa-2 was obtained
from the European Collection and Cell Cultures (ECACC,
UK). Clone #3 and Clone #8 were obtained by limitation
dilution cloning in this laboratory, adapted from [19].
The parental cell line was diluted to a concentration of 3
cells/ml and 100 μl plated onto each well of a 96-well
plate. After 24 hours each well was studied for single cells,
which were allowed to grow into colonies. Once conflu-
ence was achieved, cells were transferred to a T25-T75 cm3
flask within 2 weeks. The colonies were then screened by
invasion assay to assess their invasive abilities. Cells were
maintained in a humidified atmosphere containing 5%
CO2  at 37°C in Dulbecco's modified Eagles medium
(DMEM) supplemented with 5% foetal bovine serum
(Sigma-Aldrich). Antibiotics were not used in the growth
media. All cell lines were free from Mycoplasma as tested
with the indirect Hoechst staining method.
Invasion and Motility assays
Invasion assays were performed using an adapted method
[20]. Matrigel was diluted to 1 mg/ml in serum free
DMEM. Laminin, fibronectin and collagen type IV was
diluted to 25 μg/ml in PBS and collagen type I to 10 μg/
ml. 100 μl of ECM protein was placed into each insert
(Falcon) (8.0 μm pore size), in a 24-well plate (Costar).
The ECM coated inserts were incubated overnight at 4°C.
The following day, the ECM was allowed polymerise at
37°C for 1 hr. The inserts were then washed with serum-
free DMEM, 100 μl of complete DMEM was added to the
wells and 1 × 105/100 μl cells were then seeded onto the
insert. 500 μl of complete DMEM was added into the
underside of the well. After 24 hours incubation, the
inside of the insert was wiped with a wet cotton swab. The
under surface was gently rinsed with PBS and stained with
0.25% crystal violet for 10 minutes, rinsed again with ster-
ile water and allowed to dry. To determine total number
of invading cells, the inserts were then viewed under the
microscope and the number of cells/field in 10 random
fields were counted at 200× magnification. The average
number of cells/field was then multiplied by a factor of
140 (growth area of membrane/field area viewed at 200×
magnification (calibrated using a microscope graticule)).
The mean values were obtained from a minimum of three
individual experiments and were subjected to t-tests and
ANOVA. Motility assays were carried out in the same man-
ner as invasion assays without the addition of ECM on the
insert. Experiments were performed in triplicate.
Adhesion assay
Adhesion assays were performed using a modified
method [21]. 24-well plates were coated with 250 μl of 25
μg/ml ECM proteins (laminin, fibronectin and collagen
type IV), 10 μg/ml of collagen type I and 1 mg/ml of
matrigel. ECM proteins were incubated overnight at 4°C.
To reduce non-specific binding, 0.5 ml of 0.1% BSA-PBS
solution was added to each well and incubated for 20
minutes, then rinsed twice with sterile PBS. A single cell
suspension was obtained, 1 ml of a 2.5 × 104 cell suspen-
sion was added onto the pre-coated 24-well plates in trip-
licate and allowed to attach for 60 minutes. Blank wellsJournal of Experimental & Clinical Cancer Research 2009, 28:140 http://www.jeccr.com/content/28/1/140
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contained ECM proteins but no cells; controls were
uncoated wells with cells. After 60 minutes, the non-
adhered cells were removed by washing twice with sterile
PBS. 200 μl of freshly prepared phosphatase substrate (10
mM p-nitrophenol phosphate in 0.1 M sodium acetate,
0.1% Triton X-100 pH 5.5) was added to each well. Plates
were then incubated in the dark at 37°C for 2 hours. The
enzymatic reaction was stopped by the addition of 100 μl
1 M NaOH. The absorbance was read on a BIO-TEK plate
reader at 405 nm with a reference wavelength of 620 nm.
Anoikis assay
24-well plates were coated with 200 μl of poly-2-hydrox-
yethyl methacrylate (poly-HEMA, 12 mg/ml dissolved in
95% ethanol, Sigma) and allowed to dry overnight. 1 ml
of a single cell suspension of 1 × 105cells was plated onto
standard 24 well plates or poly-HEMA coated plates. After
24 hours incubation at 37°C in a humidified atmosphere
containing 5% CO2, the viability of cells was quantita-
tively measured using alamarBlue indicator dye (Serotec).
The absorbance was read on a BIO-TEC plate reader at 570
nm with a reference wavelength of 600 nm.
Soft agar colony-forming assay
Soft agar assays or anchorage independent growth assays
were carried out using a modified method [22]. 1.548 g of
agar (Bacto Difco, 214040) was dissolved in 100 ml of
ultra pure water and autoclaved. This agar was then
melted in a microwave oven immediately prior to use and
incubated at 44°C. 50 ml of agar was then added to 2×
DMEM AgarMedium (AgM), mixed well and quickly dis-
pensed onto 35 mm sterile petri dishes. The plates were
allowed to set at room temperature and the remaining
AgM was returned to the water bath with the temperature
reduced to 41°C. 10% FCS was added to the AgM. Cells
were harvested and resuspended in medium without
serum, ensuring that a single cell suspension was
obtained. The cells were diluted to 2 × 104 cells/ml in a
total of 5 ml. 5 ml of agar was then added to each suspen-
sion, mixed well and 1.5 ml was dispensed onto each pre-
set agar plate, in triplicate, giving a final concentration of
1.5 × 104 cells per plate. The plates were placed on trays
containing a small volume of water to prevent the agar
from drying out. On day 0, cells were counted and subse-
quently cultured for an additional 10 days. After this time
the colonies were counted using an inverted microscope
at 400×. Ten areas were viewed per plate and the total
number of colonies present was extrapolated and the per-
centage colony forming efficiency (CFE) was determined
by expressing the number of colonies formed after 10 days
as a percentage of the number of cells counted on day 0.
Immunoblotting
Whole protein was extracted from cell lysates using 1×
lysis buffer (50 mM Tris-Cl, 150 mM NaCl, and 0.5% NP-
40). Lysates were centrifuged for 10 min at 14,000 rpm at
4°C. Protein concentrations were determined using the
Bio-Rad protein assay according to manufacturer's
instructions (Bio-Rad). 35 μg of protein was separated by
7.5% SDS-PAGE under reducing conditions. Proteins
were transferred to nitrocellulose membrane (Amer-
sham). Membranes were blocked at 4°C overnight in TBS
(25 mM Tris-HCl, pH 7.4, 150 mM NaCl, 2.7 mM KCl)
containing 5% (w/v) lowfat milk powder. Membranes
were probed with specific antibodies. Anti-β1
(MAB1951Z-20), anti-α5 (AB1949) and anti-α6
(MAB1982) were obtained from Chemicon (Millipore,
Europe). Beta-actin was used as loading control (Sigma,
A5441). Membranes were washed 3× for 5 min with PBS-
Tween-20 (0.1%) and incubated with secondary antibod-
ies, anti-mouse and anti-rabbit (Sigma) for 1 hr at room
temperature and washing step repeated. Protein bands
were detected with Luminol reagent (Santa Cruz Biotech-
nology).
Integrin siRNA transfection
Two integrin β1 (ITGB1) target siRNAs (#109877,
#109878 (validated) Ambion Inc.) were used to silence
integrin β1 expression. Two integrin α5 (ITGA5) target
siRNAs (#106728, #111113 Ambion Inc.) and two
integrin α6 (ITGA6) target siRNAs (#8146, #103827 (val-
idated) Ambion Inc.) were used to silence the respective
target genes. Solutions of siRNA at a final concentration of
30 nM were prepared in OptiMEM (Gibco™). NeoFX solu-
tion was prepared in OptiMEM and incubated at room
temperature for 10 min. After incubation, an equal vol-
ume of neoFX solution was added to each siRNA solution,
mixed well and incubated for a further 10 min. 100 μl of
neoFX/OptiMEM solutions were added into a 6 well plate
in duplicate. Clone #8 (3 × 105) cells were added onto the
siRNA solution. The plates were gently mixed and incu-
bated for 24 hours. The transfection mixture was removed
and replaced with fresh medium. Positive control, kinesin
(Ambion Inc.) was included in each triplicate experiment.
Invasion, motility, adhesion and anoikis assays were then
carried out 48 hours after transfection, as previously
described.
Statistical analysis
Student's t-test was used for statistical analyses of inva-
sion, motility, adhesion, anoikis and soft agar assays. * p
≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.005 indicated statistical sig-
nificance. Data are presented as mean ± standard devia-
tion. Each experiment was repeated at least three times.
Multiple group comparison experiments were validated
by ANOVA.Journal of Experimental & Clinical Cancer Research 2009, 28:140 http://www.jeccr.com/content/28/1/140
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Results
Single cell cloning
Four clones were isolated from the pancreatic cell line,
MiaPaCa-2 and successfully established as cell lines. The
invasion status of the clones was tested using the Boyden
chamber assay with inserts coated with matrigel. Two sub-
populations, Clone #3 and Clone #8, showed a significant
increase (Clone #3, 2.5-fold increase, p  = 0.001) and
decrease (Clone #8, 12-fold decrease, p  = 0.00001),
ANOVA (p < 0.001), (Fig 1A(i-ii) and 1B) in invasion
through matrigel, compared to the parental MiaPaCa-2
cells. These two clonal populations also displayed distinct
morphological differences (Fig 1A(iii-iv)). The invasive
cell line, Clone #3 displayed an elongated spindled
shaped morphology, similar to mesenchymal cells. Clone
#8, low invasion, was similar to epithelial cells in tight
clustered colonies.
Invasion and adhesion to ECM proteins
Invasion of MiaPaCa-2 and sub-populations, Clone #3
and Clone #8, through a range of ECM proteins was exam-
ined (Fig 2A). The invasion of MiaPaCa-2 and Clone #3 is
comparable through laminin and fibronectin whereas
Clone #8 showed a significant decrease in invasion, 6.3
and 4.0-fold (p = 0.002, p = 0.008) through laminin and
fibronectin, respectively, ANOVA (all p  < 0.001). Low
invasion was observed for Clone #3 through collagens
type I and IV; Clone #8 showed significantly decreased
invasion through the collagens (1.6 and 1.6-fold (p  =
0.03, p = 0.02)), ANOVA (p = 0.007, p = 0.001). Interest-
ingly, the lowest level of invasion displayed by the cell
lines was through the collagens, type IV and I, which is in
agreement with previous studies indicating MiaPaCa-2
does not express collagen-binding integrins [23]. The
highest level of invasion was observed through fibronec-
tin. Clone #3 also displayed significantly increased motil-
ity (p = 0.00005) whereas the motility of Clone #8 was
similar to that of MiaPaCa-2, ANOVA (p < 0.001) (Fig
2A).
The more invasive Clone #3, displays significantly
decreased adhesion to matrigel (p = 0.01), laminin (p =
0.02), fibronectin (p = 0.01) and collagen type IV (p =
0.01) compared to the parental cell line (Fig 2B). In con-
trast a significant increase in adhesion was observed to
collagen type I (p = 0.003), although the level of adhesion
to the collagens was significantly lower than that to
fibronectin or laminin. The less invasive Clone #8,
showed significantly increased adhesion to matrigel (p =
0.04) and laminin (p = 0.002). Adhesion to fibronectin
and collagen type I were also increased, but not signifi-
cantly and adhesion to collagen type IV was decreased sig-
nificantly (p = 0.001) for Clone #8.
Anoikis and anchorage-independent growth
The evaluation of survival in suspension (anoikis)
showed that Clone #3 was resistant to anoikis compared
to the parental cell line, although this difference did not
reach statistical significance (p = 0.07). Clone #8 demon-
strated a significant sensitivity to anoikis (p = 0.02) com-
pared to the parental cell line, MiaPaCa-2 (Fig 3A).
Anchorage-independent growth was assessed using the
soft agar assay. MiaPaCa-2 showed colony formation with
an average colony size of 75 μm and percentage colony
forming efficiency (% CFE) of 48%; Clone #3 formed
more and larger colonies with an average size of 120 μm
and a %CFE of 69%. In contrast, Clone #8 (low invasion
and high adhesion), showed significantly reduced ability
(32% CFE) to form colonies (p = 0.006) and the average
size of colonies was 60 μm (Fig 3B).
Integrin expression
Significant changes in invasion and adhesion to fibronec-
tin and laminin were observed in the sub-populations.
Therefore, expression of integrins β1, α5 and α6, which
are associated with adhesion to laminin and fibronectin
were examined in the cell lines, by immunoblotting (Fig
4A-C). Beta-actin used as loading control (Fig 4D). Com-
pared to MiaPaCa-2, Clone #8 showed higher expression
of integrins β1 and α5. Low levels of α6 were detected in
Clone #8, while it was undetectable in the parental Mia-
PaCa-2 cells. Lower levels of each of the integrins were
detected in Clone #3 compared to Clone #8.
Integrin β1 knockdown
The role of integrin β1 in the low invasive cell line, Clone
#8 was investigated using RNAi. Clone #8 was chosen as
it expresses high levels of integrin β1 compared to Clone
#3 (Fig 4A). Cells were subjected to invasion, motility,
adhesion and anoikis assays following siRNA transfec-
tion. SiRNA knockdown of protein was confirmed by
immunoblot (Fig 4E). Integrin β1 siRNA transfected into
Clone #8 resulted in a significant increase in invasion
through matrigel (p = 0.005 and p = 0.04), ANOVA (p =
0.006), although invasion through laminin was not sig-
nificantly altered. Invasion through fibronectin was sig-
nificantly increased (p = 0.04 and p = 0.02), ANOVA (p =
0.02). Motility of Clone #8 after siRNA β1 transfection
was also significantly increased (p = 0.01 and p = 0.03)
compared to the scrambled control, ANOVA (p = 0.003)
(Fig 5A). A significant decrease in adhesion to matrigel
(45-47%) was observed (p = 0.02 and p = 0.002), ANOVA
(p = 0.002), while adhesion to fibronectin (p = 0.02 and p
= 0.04), ANOVA (p = 0.01) was significantly decreased
with the integrin β1 siRNA treatment (Fig 5B). Adhesion
to laminin was not altered after transfection with integrin
β1 siRNAs. Anoikis assays were also carried out to investi-
gate whether the knockdown of integrin β1 had any effect
on the survival of Clone #8 in suspension (Fig 5C). A sig-Journal of Experimental & Clinical Cancer Research 2009, 28:140 http://www.jeccr.com/content/28/1/140
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A. Morphology of the highly invasive (i) Clone #3 with elongated and spindle-like phenotype and low-invasive (ii) Clone #8 with  epithelial tight colonies Figure 1
A. Morphology of the highly invasive (i) Clone #3 with elongated and spindle-like phenotype and low-invasive 
(ii) Clone #8 with epithelial tight colonies. Cell invasion assay representing (iii) Clone #3 and (iv) Clone #8 invading 
through ECM coated Boyden chamber, stained with crystal violet. Magnification 200×. Scale bar, 200 μm. B. Total number of 
invading cells. Results shown are a minimum of three repeats ± standard deviation (n = 3).Journal of Experimental & Clinical Cancer Research 2009, 28:140 http://www.jeccr.com/content/28/1/140
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A. Invasion assay of MiaPaCa-2, Clone #3 and Clone #8 through ECM proteins Figure 2
A. Invasion assay of MiaPaCa-2, Clone #3 and Clone #8 through ECM proteins. Motility assay refers to invasion 
assay without the presence of ECM. Results are displayed as the total mean number of cells invading at 200× magnification (n = 
3). B. Adhesion of MiaPaCa-2, Clone #3 and Clone #8 to ECM proteins: matrigel, laminin, fibronectin, collagen type IV 
(ANOVA, all p < 0.001) and collagen I (ANOVA p = 0.04). Results are expressed as absorbance at 405 nm with a reference 
wavelength of 620 nm. Data shown is mean ± standard deviation (n = 3). Student's t-test; p ≤ 0.05*, 0.01**, 0.005***.Journal of Experimental & Clinical Cancer Research 2009, 28:140 http://www.jeccr.com/content/28/1/140
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A. Percentage survival of MiaPaCa-2, Clones #3 and Clone #8 in suspension compared to adherent cells, ANOVA (p = 0.002) Figure 3
A. Percentage survival of MiaPaCa-2, Clones #3 and Clone #8 in suspension compared to adherent cells, 
ANOVA (p = 0.002). B. Percentage colony formation efficiency (%CFE) of MiaPaCa-2, Clone #3 and Clone #8 under anchor-
age-independent growth conditions, ANOVA (p = 0.02). Data shown is mean ± standard deviation (n = 3). Student's t-test; p ≤ 
0.05*, 0.01**, 0.005***.Journal of Experimental & Clinical Cancer Research 2009, 28:140 http://www.jeccr.com/content/28/1/140
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nificant increase in the percentage of cells surviving in sus-
pension was observed after treatment with integrin β1
siRNA compared to cells treated with scrambled control (p
= 0.01, p = 0.003), ANOVA (p = 0.005)
Integrin α5 and α6 knockdown
To further evaluate the role of specific integrins in inva-
sion, motility, adhesion and anoikis, siRNA experiments
targeting α5 and α6 integrins were also carried out in
Clone #8 cells (Fig 4F-G). Transfection of integrin α5
siRNA into Clone #8 resulted in an increase in invasion
through matrigel (p = 0.0003, p = 0.005), ANOVA (p <
0.001) laminin (p = 0.07, p = 0.008), ANOVA (p = 0.001)
and fibronectin (p = 0.0002, p = 0.0001), ANOVA (p <
0.001) compared to the scrambled control. Transfection
of siRNA α6 into Clone #8 resulted in a significant
increase in invasion through matrigel (p = 0.00009 and p
= 0.02), ANOVA (p < 0.001) and fibronectin (p = 0.004
and p = 0.04), ANOVA (p = 0.04), with no significant
increase in invasion through laminin (Fig 6A). Knock-
Immunoblot of A. Integrin β1 B. Integrin α5 C. Integrin α6 and D. β-actin used as loading control in MiaPaCa-2, Clone #3 and  Clone #8 Figure 4
Immunoblot of A. Integrin β1 B. Integrin α5 C. Integrin α6 and D. β-actin used as loading control in MiaPaCa-
2, Clone #3 and Clone #8. E. Knockdown of integrin β1 in Clone #8 cells 48 hours post transfection (siRNAs ITGβ1 #1 and 
#2). F. Knockdown of integrin α5 in Clone #8 cells 48 hours post transfection (siRNAs ITGα5 #1, #2). G. Knockdown of 
integrin α6 in Clone #8 cells 48 hours post transfection (siRNAs ITGα6 #1 and #2). H. Beta-actin used as loading control.Journal of Experimental & Clinical Cancer Research 2009, 28:140 http://www.jeccr.com/content/28/1/140
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A. Invasion of Clone #8 through matrigel, laminin and fibronectin and motility assay Figure 5
A. Invasion of Clone #8 through matrigel, laminin and fibronectin and motility assay. B. Adhesion assay of Clone 
#8 to matrigel, laminin and fibronectin. C. Anoikis assay. Experiments were performed 48 hours post-transfection with two dif-
ferent exon targeted siRNA integrin Beta 1. Student's t-test; p ≤ 0.05*, 0.01**, 0.005***.Journal of Experimental & Clinical Cancer Research 2009, 28:140 http://www.jeccr.com/content/28/1/140
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down of integrin α5 resulted in significantly increased
motility, ANOVA (p = 0.007) while integrin α6 knock-
down also increased motility significantly in one siRNA (p
= 0.19 and p = 0.004), ANOVA (p = 0.04) (Fig 6B).
A slight decrease in adhesion to matrigel and laminin was
observed although not significantly, while a significant
reduction in adhesion to fibronectin was observed after
integrin α5 siRNA treatment of Clone #8 cells (p = 0.02, p
= 0.03), ANOVA (p = 0.02). Adhesion to matrigel and
fibronectin was not altered with integrin α6 siRNA treat-
ment; however adhesion to laminin was reduced (p = 0.08
and p = 0.01), ANOVA (p = 0.01) (Fig 6C). No significant
change in anoikis response was observed after either
integrin α5 and α6 siRNA transfection, compared to cells
treated with scrambled control (Fig 6D).
Discussion
One of the most lethal aspects of pancreatic cancer is its
early systemic dissemination and tumour progression
[24]. The inability to diagnose pancreatic cancer at an
early stage has contributed to poor prognosis, as well as
the difficulties in treating the metastatic disease. The exact
mechanism of pancreatic invasion and metastasis has not
been fully elucidated and a better understanding of these
processes is essential in treating this disease.
To study the inherent heterogeneity of differing sub-pop-
ulations within a tumour, we isolated isogenic clonal pop-
ulations from the human pancreatic cell line, MiaPaCa-2,
by single cell cloning. Two sub-populations displaying
differences in invasion were further analysed to character-
ise the in vitro invasive phenotype. Clone #3 was charac-
A. Invasion through matrigel, laminin and fibronectin Figure 6
A. Invasion through matrigel, laminin and fibronectin. B. Motility assay. C. Adhesion assay to matrigel, laminin and 
fibronectin. D. Anoikis assay of Clone #8 control, treated with scrambled siRNA, two independent integrin ITGα5 siRNA tar-
gets and two integrin ITGα6 target siRNAs. Student's t-test; p ≤ 0.05*, 0.01**, 0.005***.Journal of Experimental & Clinical Cancer Research 2009, 28:140 http://www.jeccr.com/content/28/1/140
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terised as highly invasive and motile with decreased
adhesion to ECM proteins. The less invasive Clone #8 dis-
played increased adhesion to ECM proteins. Neither clone
showed an affinity to collagen type I and IV. Grzesiak et al.
[23] previously determined that the parental cell line Mia-
PaCa-2 does not express collagen-binding integrins α1
and α2, but showed that the cells are metastatic in an
orthotopic mouse model and preferentially migrate on
laminin-1. Although collagen type IV constitutes the
major intrinsic component of the extracellular matrix
[25], the ability of the clonal populations in our study to
invade or/adhere to matrigel could be due to laminin,
another major component of the ECM, and to a lesser
extent fibronectin, which represents a significant step in
metastasis [26]. Changes in adhesive characteristics, inva-
sion and motility of cells have been suspected to play a
role in mediating the spread of malignant cells.
Clone #3 displays the characteristics of an aggressive can-
cer, with decreased adhesion facilitating increased motil-
ity and invasion, coupled with the ability to survive and to
form colonies in anchorage independent conditions.
These features could be compared to the in vivo situation
where the ability of tumour cells to detach from the pri-
mary tumour, invade through the ECM, survive in the
blood stream, and invade and form tumours at secondary
sites, leads to the formation of metastases. Therefore, we
believe that Clone #3 represents an in vitro model of
tumour cells with increased metastatic potential. In con-
trast Clone #8 appears to be a model of tumour cells with
decreased metastatic potential, showing decreased inva-
sion, increased adhesion, increased sensitivity to anoikis
and reduced ability to grow and form colonies in anchor-
age-independent conditions.
Integrins are involved in regulating growth, differentia-
tion, and death by regulating the interaction between cell
and ECM [7]. In pancreatic cancer, links have previously
been established between increased invasion and
decreased adhesion to ECM proteins in vitro and to high
metastatic potential in vivo [27-29].
In general, the loss or gain of expression of individual
integrins appears to be indirectly associated with malig-
nant transformation and involved in tumour progression
and metastasis. Over expression of α5β1 in CHO cells
demonstrated reduced malignancy [30], whereas α2β1
and α3β1 were expressed in non-neoplastic and fibroade-
nomas but were low or absent in highly invasive mam-
mary carcinomas [31]. In our study, Clone #3 showed
reduced expression of integrins β1, α5 and α6 compared
to Clone #8, which correlates with the reduced adhesion
to laminin and fibronectin, as integrin α5β1 is a receptor
for fibronectin and α6β1 is a receptor for laminin [32,26].
Integrin β1, α5 and α6 siRNA transfection in Clone #8
resulted in significantly increased motility and invasion
through matrigel and fibronectin, and reduced adhesion
to matrigel and fibronectin. Loss of integrin β1 did not
alter the invasion or adhesion of Clone #8 cells to lam-
inin, but loss of α6 significantly reduced adhesion to lam-
inin. These results suggest that inhibition of integrin β1
alone is not sufficient to block adhesion to laminin. Other
integrin complexes such as α6β4 [33] could control lam-
inin-mediated adhesion/invasion in these cells. Gilcrease
et al. [34] showed that α6β4 cross linking in suspended
non adherent breast cancer cells resulted in cell surface
clustering of EGFR, increasing EGFR-mediated activation
of Rho in response to EGF, which may lead to tumour cell
migration. Knockdown of the expression of integrin β1 in
Clone #8 also revealed a more anoikis resistant pheno-
type. Disruption of β1 integrin complexes has previously
implicated in induction of anoikis [35-37]. These experi-
ments support the hypothesis that decreased expression of
these integrins β1, α5 and α6, in Clone #3 plays a role in
the aggressive invasive phenotype observed in vitro.
Reduced expression of integrin β1, but not α5 and α6,
appears to play an important role in anoikis resistance in
this model. Therefore, targeting of integrins specific to cer-
tain tumours may provide viable options for therapeutic
treatment.
Conclusion
We have established that sub-populations within a pan-
creatic cancer cell line display varied invasion and adhe-
sive interactions with ECM proteins. Low adhesion, high
motility and invasion, reduced integrin α5, α6 and β1
expression, anoikis resistance and anchorage-independ-
ent growth in Clone #3 represents a highly invasive phe-
notype. This is the first study to report the relationship
between invasion, adhesion, anoikis and anchorage inde-
pendent colony formation within sub-populations of a
pancreatic cancer cell line. In vivo analysis of these clonal
populations of MiaPaCa-2 will be required to determine if
the aggressive invasive phenotype in vitro correlates with
increased metastatic potential in vivo. Further investiga-
tion of this aggressive phenotype may help to identify
novel markers and targets for invasion and metastasis in
pancreatic cancer.
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